临床肺科杂志
臨床肺科雜誌
림상폐과잡지
JOUNAL OF CLINICAL PULMONARY MEDICINE
2014年
7期
1303-1304,1305
,共3页
周洋%黄河%张家洪%龚建化
週洋%黃河%張傢洪%龔建化
주양%황하%장가홍%공건화
博莱霉素%热疗%恶性胸腔积液
博萊黴素%熱療%噁性胸腔積液
박래매소%열료%악성흉강적액
bleomycin%thermotherapy%malignant pleural effusion
目的:观察博莱霉素联合局部热疗治疗非小细胞肺癌( NSCLC)恶性胸腔积液的临床疗效。方法将50例NSCLC恶性胸腔积液的患者随机分为两组,采用胸腔穿刺术置入中心静脉导管引流胸腔积液,待排尽胸腔积液后,对照组给予胸腔灌注博莱霉素,实验组在对照组的基础上给予患者局部热疗,比较两组治疗情况、毒副反应及生活质量改善情况。结果两组患者治疗后,实验组患者的生活质量KPS评分及控制胸水的总有效率均明显高于对照组(P<0.05),且不良反应明显少于对照组(P<0.05)。结论博莱霉素联合局部热疗治疗NSCLC恶性胸腔积液具有协同作用,值得临床推广。
目的:觀察博萊黴素聯閤跼部熱療治療非小細胞肺癌( NSCLC)噁性胸腔積液的臨床療效。方法將50例NSCLC噁性胸腔積液的患者隨機分為兩組,採用胸腔穿刺術置入中心靜脈導管引流胸腔積液,待排儘胸腔積液後,對照組給予胸腔灌註博萊黴素,實驗組在對照組的基礎上給予患者跼部熱療,比較兩組治療情況、毒副反應及生活質量改善情況。結果兩組患者治療後,實驗組患者的生活質量KPS評分及控製胸水的總有效率均明顯高于對照組(P<0.05),且不良反應明顯少于對照組(P<0.05)。結論博萊黴素聯閤跼部熱療治療NSCLC噁性胸腔積液具有協同作用,值得臨床推廣。
목적:관찰박래매소연합국부열료치료비소세포폐암( NSCLC)악성흉강적액적림상료효。방법장50례NSCLC악성흉강적액적환자수궤분위량조,채용흉강천자술치입중심정맥도관인류흉강적액,대배진흉강적액후,대조조급여흉강관주박래매소,실험조재대조조적기출상급여환자국부열료,비교량조치료정황、독부반응급생활질량개선정황。결과량조환자치료후,실험조환자적생활질량KPS평분급공제흉수적총유효솔균명현고우대조조(P<0.05),차불량반응명현소우대조조(P<0.05)。결론박래매소연합국부열료치료NSCLC악성흉강적액구유협동작용,치득림상추엄。
Objective To observe the clinical effect of bleomycin combined with local thermotherapy in the treatment of NSCLC patients with malignant pleural effusion. Methods 50 NSCLC patients with malignant pleural effusion were randomly divided into two groups. All patients were treated with thoracentesis and inserted central ve-nous catheter to drainage pleural effusion. After exhaustion of pleural effusion, the control group was treated with ble-omycin by pleural perfusion, and the experiment group was treated with local thermotherapy on the base of the control group. The treatment, side effect and quality of life were compared. Results After the treatment, the KPS scores of living quality and the total effective rate of controlling pleural effusion were better in the experiment group than in the control group (P<0. 05), and the side effect was significant lower in the experiment group than in the control group (P<0. 05). Conclusion Bleomycin combined with local thermotherapy has a synergistic effect in the treatment of NSCLC with malignant pleural effusion.